CORONA Remedies Limited
All news and filings related to CORONA Remedies Limited.
View all news & filings- Medium impact
CORONA Remedies: CARE Ratings Reaffirms A+ Stable for ₹7 Cr LT Bank Facilities, Upgrades ₹70 Cr LT/ST Facilities
CORONA Remedies Limited's ₹7 crore Long Term Bank Facilities rating reaffirmed as CARE A+; Stable. ₹70 crore Long Term/Short Term Facilities upgraded to CARE A+; Stable / CARE A1+. Ratings based on FY26 audited and Q1FY27 unaudited performance. Total rated facilities ₹77 crore.
Read the summary - Low impact
CORONA Remedies Limited: Trading Window Closure for Q2 FY27 Financial Results
CORONA Remedies Limited will close its trading window from October 01, 2026, until 48 hours after the declaration of Q2 FY27 financial results. The board meeting date for approving these results will be announced later.
Read the summary - Low impact
CORONA Remedies to Meet JP Morgan Group on Sep 23, 2026
CORONA Remedies Limited will hold a meeting with JP Morgan Group on September 23, 2026, in Ahmedabad. The discussions will be limited to publicly available information, with no UPSI to be shared. This is an investor/analyst meet.
Read the summary - Low impact
CORONA Remedies Limited Clarifies Volume Surge, Cites Market Driven Activity
CORONA Remedies Limited clarified a recent surge in its share trading volume, stating it is purely market-driven. The company confirmed no undisclosed price-sensitive information or impending corporate actions are pending.
Read the summary - Low impact
CORONA Remedies to Participate in Phillip Capital Investor Conference on Aug 26
CORONA Remedies Limited officials will attend an investor conference organized by Phillip Capital PCG Group in Ahmedabad on August 26, 2026. The meeting, starting at 11:00 AM IST, will focus on publicly available information.
Read the summary - High impact
CORONA Remedies Q1 FY27 Earnings Call Transcript Released
CORONA Remedies reported Q1 FY27 revenue of ₹422 Cr, up 21.9% YoY. EBITDA grew 33.5% to ₹93 Cr, and PAT increased 30.1% to ₹60 Cr. The company outperformed the IPM with 22.7% India business growth. Management reaffirmed FY27 guidance of 15% organic revenue growth and 20% PAT growth.
Read the summary - Low impact
CORONA Remedies to Participate in Emkay and Equirus Investor Conferences
CORONA Remedies Limited officials will attend investor conferences organized by Emkay Global on August 13, 2026, and Equirus on August 14, 2026, both in Mumbai. The meetings will be in-person and based on publicly available information.
Read the summary - High impact
CORONA Remedies Q1FY27 Revenue Up 21.9% to ₹422.4 Cr, PAT Grows 30.1%
CORONA Remedies reported Q1FY27 revenue of ₹422.4 Cr, up 21.9% YoY. PAT grew 30.1% YoY to ₹60.1 Cr, with margins at 14.2%. The company inaugurated a new EU-GMP approved Female Hormone Manufacturing Facility on June 30, 2026. CORONA continues to outperform IPM growth.
Read the summary - Low impact
CORONA Remedies Q1 FY27 Earnings Call Audio Recording Available
CORONA Remedies Limited released the audio recording of its Q1 FY27 earnings conference call, which covered the unaudited financial results for the period ended June 30, 2026. The recording is accessible on the company's website.
Read the summary - Low impact
Corona Remedies Publishes Q1 FY27 Unaudited Financial Results
CORONA Remedies Limited has published its unaudited financial results for the quarter ended June 30, 2026. The results were approved by the Board of Directors on July 31, 2026, and published in the Financial Express.
Read the summary - High impact
CORONA Remedies Q1FY27: Revenue surges 21.9% to ₹422.4 Cr, PAT up 30.1% to ₹60.1 Cr
CORONA Remedies reported Q1FY27 revenue of ₹422.4 crore, a 21.9% year-on-year increase. PAT rose 30.1% to ₹60.1 crore with a 14.2% margin. EBITDA grew 33.5% to ₹93.1 crore with a 22.0% margin. The company is the fastest growing in IPM, improved EU-GMP certifications, and inaugurated a new hormone facility.
Read the summary - High impact
CORONA Remedies Q1FY27 Revenue up 21.9% to ₹422.4 Cr, PAT grows 30.1%
CORONA Remedies reported Q1FY27 unaudited results with revenue up 21.9% to ₹422.4 Cr and PAT up 30.1% to ₹60.1 Cr. The company inaugurated its EU-GMP approved Female Hormone Manufacturing Facility on June 30, 2026. CORONA continues to be the fastest-growing company among top 30 IPM companies.
Read the summary - High impact
CORONA Remedies Q1FY27 Revenue Up 21.9% to ₹422.4 Cr, PAT Grows 30.1%
CORONA Remedies reported Q1FY27 revenue of ₹422.4 Cr, a 21.9% Y-o-Y growth. PAT increased by 30.1% to ₹60.1 Cr with margins at 14.2%. The company is the fastest growing in IPM for six months and ranks 26th. A new EU-GMP approved Female Hormone Facility was inaugurated on June 30, 2026.
Read the summary - Low impact
CORONA Remedies Schedules Q1 FY27 Earnings Call for Aug 3, 2026
CORONA Remedies Limited will hold its Q1 FY27 earnings conference call on August 3, 2026, at 11:30 a.m. IST to discuss financial results for the quarter ended June 30, 2026. Management team members will be present.
Read the summary - Medium impact
CORONA Remedies Limited holds 22nd AGM, approves final dividend of ₹10 per share.
CORONA Remedies Limited held its 22nd AGM on July 9, 2026. Key decisions included approving the FY26 financial statements, declaring a final dividend of ₹10 per share, re-appointing Mr. Nirav Mehta, and appointing new statutory and secretarial auditors. Dr. Kirtikumar Mehta was re-appointed as Non-Executive Director and Chairman for 5 years.
Read the summary - Low impact
CORONA Remedies: Reg. 74(5) Certificate for Q1 FY27 Confirms Shares in Demat Form
CORONA Remedies Limited received a certificate for the quarter ended June 30, 2026, confirming that Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, is not applicable. This is due to the company's entire shareholding being in demat form, with no rematerialisation requests received.
Read the summary - Medium impact
CORONA Remedies Commences Production at Advanced EU-GMP Women's Hormone Facility
CORONA Remedies has commenced commercial production at its new EU-GMP approved Women's Hormone manufacturing facility in Bhayla, Ahmedabad. The facility has an annual capacity of 194 million tablets/capsules and 1.5 million ointments/gels, increasing the company's in-house hormone manufacturing capacity by nearly 20%. The facility aims to serve both domestic and international markets.
Read the summary - Low impact
CORONA Remedies: Trading Window Closed July 1 for Q1 FY27 Results
CORONA Remedies Limited will close its trading window from July 01, 2026, until 48 hours after the declaration of Q1 FY27 financial results. The board meeting date for considering these results will be announced separately.
Read the summary - Low impact
CORONA Remedies Announces 22nd AGM, Record Date for Dividend, and E-voting
CORONA Remedies Limited announced its 22nd Annual General Meeting. The notice includes the record date for dividend and e-voting information. Advertisements were published on June 16, 2026, in Financial Express (English and Gujarati) and are available on the company website.
Read the summary - Medium impact
CORONA Remedies: 22nd AGM on July 9, 2026; ₹10 dividend proposed.
CORONA Remedies Limited will hold its 22nd AGM on July 9, 2026. The Board has recommended a dividend of ₹10 per equity share for FY 2025-26, subject to member approval at the AGM. Shareholders need to update KYC details for electronic dividend payment.
Read the summary - Low impact
CORONA Remedies Announces 22nd AGM on July 9, 2026; July 2 Cut-off Date
CORONA Remedies Limited will hold its 22nd Annual General Meeting on July 9, 2026, via video conference. July 2, 2026, is the cut-off date for voting eligibility. The company reported FY26 revenue of ₹1,403.18 Crores, Operating Profit of ₹293.44 Crores, and PAT of ₹199.42 Crores.
Read the summary - Low impact
CORONA Remedies Announces 22nd AGM on July 9, 2026, via VC/OAVM
CORONA Remedies Limited will hold its 22nd Annual General Meeting on July 9, 2026, at 11:00 a.m. IST. The meeting will be conducted via Video Conferencing / Other Audio Visual Means (VC / OAVM).
Read the summary - Low impact
CORONA Remedies to Meet Investors on June 8-9, 2026 in Singapore
CORONA Remedies Limited officials will participate in investor meetings organized by IIFL Capital on June 8-9, 2026, in Singapore. Discussions will be limited to publicly available information.
Read the summary - Low impact
CORONA Remedies to Meet Investors on June 4-5
CORONA Remedies Limited will participate in a Non-Deal Roadshow (NDR) to meet investors. The meetings, organized by JM Financial, are scheduled for June 04-05, 2026, in Mumbai. Discussions will be limited to publicly available information.
Read the summary - Medium impact
CORONA Remedies Secures EU-GMP Certifications for Hormone and OSD Facilities
CORONA Remedies Limited received EU-GMP certification for its Hormone facility and renewed approval for its Oral Solid Dosage (OSD) facility after an April 2026 inspection. This strengthens global manufacturing and quality credentials, aiming to serve Indian and international markets.
Read the summary - Low impact
CORONA Remedies to deduct TDS on dividend; deadline June 19, 2026
CORONA Remedies recommended a final dividend of ₹10 per share. Shareholders must update details by June 19, 2026, for TDS compliance. Tax rates vary based on residency and documentation. Dividend payment is subject to AGM approval.
Read the summary - Low impact
CORONA Remedies to Participate in Ambit & 360 ONE Investor Conferences
CORONA Remedies Limited officials will attend the "Ambit India Access - Titans of Tomorrow" conference on May 26, 2026, and the "TRINITY INDIA 2026" conference on May 27, 2026. Both events will be held in Mumbai and will focus on publicly available information.
Read the summary - High impact
CORONA Remedies FY26 Revenue Up 17% to ₹1,403 Crore; PAT Jumps 33% & Dividend of ₹210/Share
CORONA Remedies reported a 17% increase in FY26 revenue to ₹1,403 crore and a 33% rise in PAT. The company declared a dividend of ₹210 per share. Two brands surpassed ₹100 crore in revenue. Strategic acquisitions, including Wokadine, and biosimilar launches contributed to growth. CORONA expects 15% revenue growth organically and 25% revenue growth in acquired brand with 20% plus PAT growth in FY27 too. The company is undertaking the expansion of its manufacturing capabilities through the addition of a new 600-kg line expansion, alongside the commissioning of our dedicated hormone manufacturing plant, which is expected to become operational in Q1 or Q2 of FY27.
Read the summary - Low impact
CORONA Remedies Files Annual Secretarial Compliance Report for FY26
CORONA Remedies Limited has submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report confirms compliance with SEBI regulations, including LODR, insider trading, and corporate governance norms. The company maintained its website, had no director disqualifications, and followed proper board processes.
Read the summary - Low impact
CORONA Remedies: Q4 FY26 Earnings Call Audio Available Online
CORONA Remedies Limited has released the audio recording of its conference call discussing Q4 and FY26 financial results. The recording is available on the company's website.
Read the summary - Low impact
CORONA Remedies Limited Announces Audited Financial Results for Q4FY26
CORONA Remedies Limited announced its audited standalone and consolidated financial results for the fourth quarter and year ended March 31, 2026. The Board of Directors approved these results on May 11, 2026. The company published the results in the Financial Express newspaper and made them available on its website.
Read the summary - High impact
CORONA Remedies Investor Presentation: Q4 & FY26 Results, Strategic Acquisitions & Expansion
CORONA Remedies reported FY26 revenue of ₹1,403.2 crore, up 17.3% YoY. Q4FY26 revenue grew 20.2% to ₹353.1 crore. Strategic acquisitions include Wokadine® for ~₹648 crore and 7 brands from Bayer Zydus. EAEU-GMP certification obtained for Bhayla facility. FY26 Adjusted PAT was ₹199.4 crore (+33.4% YoY).
Read the summary - Medium impact
CORONA Remedies Board Approves FY26 Results, Recommends ₹10 Dividend
CORONA Remedies approved audited standalone and consolidated financial results for Q4FY26 and FY26. The board recommended a final dividend of ₹10 per share. M/s. Walker Chandiok & Co LLP was recommended as Statutory Auditors for five years. Dr. Kirtikumar Mehta's reappointment as Director and Chairman was also approved.
Read the summary - Medium impact
CORONA Remedies Board Approves FY26 Results, Recommends Dividend, Appoints New Auditors
CORONA Remedies Limited reported audited standalone and consolidated financial results for Q4FY26 and FY26. The board recommended a final dividend of ₹10 per share. Key appointments include M/s. Walker Chandiok & Co LLP as Statutory Auditors for five years, and Dr. Kirtikumar Mehta as Non-Executive Director and Chairman for five years.
Read the summary - High impact
CORONA Remedies FY26 PAT Up 33.4% to ₹199.4 Cr; Acquires WOKADINE
CORONA Remedies reported FY26 revenue of ₹1,403.2 Cr, up 17.3% YoY, and PAT of ₹199.4 Cr, up 33.4% YoY. Q4FY26 revenue grew 20.2% to ₹353.1 Cr, with PAT up 43.7% to ₹45.3 Cr. The company acquired WOKADINE, entering the ₹648 Cr Povidone Iodine market, and relaunched key brands.
Read the summary - Medium impact
CORONA Remedies Q4 FY26 Results: Board Approves Unmodified Financials & ₹10 Dividend
CORONA Remedies Limited announced its audited standalone and consolidated financial results for Q4 FY26. The company recommended a final dividend of ₹10 per share. Key auditor appointments and re-appointments were approved, including Statutory Auditors for five years. Dr. Kirtikumar Mehta's re-appointment as Chairman was also recommended.
Read the summary - Medium impact
CORONA Remedies to Host Q4 FY26 Earnings Call on May 12, 2026
CORONA Remedies Limited will hold its Q4 FY26 earnings conference call on May 12, 2026, at 11:00 AM IST. The call will discuss financial results for the quarter and year ended March 31, 2026. Management representatives will include MD & CEO Nirav Mehta and CFO Bhavin Bhagat.
Read the summary - Low impact
CORONA Remedies: Reg 74(5) Certificate for Q4 FY26 Not Applicable
CORONA Remedies Limited received a certificate for Q4 FY26 stating Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, is not applicable. This is due to the company's shares being entirely in demat form with no rematerialization or dematerialization requests received during the quarter ended March 31, 2026.
Read the summary - Medium impact
CORONA Remedies Acquires Wokadine® from Dr. Reddy's for ₹648 Cr
CORONA Remedies acquired Wokadine® from Dr. Reddy's for ₹648 crore. This is CORONA's fifth acquisition and enters them into the Povidone Iodine market. The deal is funded by internal accruals.
Read the summary - Low impact
CORONA Remedies: Trading Window Closed from April 1 for Q4/FY26 Results
CORONA Remedies Limited will close its trading window from April 1, 2026, until 48 hours after the declaration of its audited financial results for Q4 and FY26, ending March 31, 2026. The board meeting date for result declaration will be intimated later.
Read the summary - Low impact
CORONA Remedies to Hold Investor Meeting on March 12, 2026
CORONA Remedies Limited will host an investor and analyst meeting on March 12, 2026, at its Ahmedabad office. Discussions will focus on publicly available information.
Read the summary - Low impact
CORONA Remedies to Hold Analyst/Investor Meeting on March 6, 2026
CORONA Remedies Limited will host an Analyst/Investor Group Meeting on March 6, 2026, at 4:30 PM IST. Discussions will be limited to publicly available information, with no unpublished price-sensitive information to be shared. The meeting will take place at the company's registered office.
Read the summary - Low impact
CORONA Remedies to Participate in Investor Conferences on Feb 23-24, 2026
CORONA Remedies Limited will attend investor conferences on February 23 and 24, 2026, in Mumbai. The meetings are hosted by Kotak Institutional Equities Group and IIFL Capital Group. Discussions will be limited to publicly available information.
Read the summary - High impact
CORONA Remedies Q3 FY26: Revenue Up 15% to ₹342 Cr, PAT Grows 24%
CORONA Remedies reported Q3 FY26 revenue of ₹342 Cr, up 15% YoY, and PAT of ₹56 Cr, up 24% YoY. For 9M FY26, revenue reached ₹1,050 Cr (up 16%), and PAT was ₹154 Cr (up 31%). The company is the fastest-growing among top 30 Indian pharma firms, with an 18.9% growth in Q3 FY26. It expects mid-teen revenue growth and high-teen PAT growth going forward.
Read the summary - Low impact
CORONA Remedies Q3FY26 Earnings Call Audio Recording Available
CORONA Remedies Limited has released the audio recording of their Q3 FY26 earnings call, which covers the financial results for the third quarter and nine months ended December 31, 2025. The recording is available on the company's website.
Read the summary - Low impact
Corona Remedies Q3 FY26 Results Approved; Newspaper Ad Published
CORONA Remedies Limited's Board approved the unaudited financial results for Q3 FY26 and nine months ended Dec 31, 2025. Newspaper advertisements of these results were published on February 03, 2026. The results are also available on the company's website.
Read the summary - Medium impact
CORONA Remedies Presents Investor Presentation for Feb 2026
CORONA Remedies reported Q3 FY26 revenue of ₹342 Cr (up 15.0% YoY) and 9M FY26 revenue of ₹1,050 Cr (up 16.3% YoY). EBITDA for 9M FY26 was ₹231 Cr, and Adjusted PAT was ₹154 Cr. The company secured EAEU-GMP certification for its Bhayla facility, enabling entry into Eurasian markets. Chronic therapies formed 71.6% of 9M FY26 revenue.
Read the summary - Medium impact
CORONA Remedies Limited: CARE Ratings Reaffirms 'CARE A+; Stable' on Bank Facilities
CORONA Remedies Limited's bank facilities have been reaffirmed with a 'CARE A+; Stable' rating by CARE Rating Limited. This includes ₹25.00 crore in long-term facilities and ₹70.00 crore in long-term/short-term facilities. The reaffirmation is based on the company's performance in FY25 and H1FY26.
Read the summary - High impact
CORONA Remedies Q3 FY26 Revenue Up 15% to ₹342.42 Cr, PAT Rises 23.7%
CORONA Remedies reported Q3 FY26 consolidated revenue of ₹342.42 Cr, up 15.0% YoY, and PAT of ₹55.56 Cr, up 23.7% YoY. Nine-month FY26 revenue reached ₹1050.09 Cr (up 16.3% YoY) and PAT was ₹154.08 Cr (up 30.7% YoY). MD & CEO Nirav K. Mehta noted consistent growth and outperformance.
Read the summary - High impact
CORONA Remedies Q3 FY26: Revenue up 15%, PAT up 23.7% YoY
CORONA Remedies reported a strong Q3 FY26 with consolidated revenue up 15.0% YoY to ₹342.42 Cr and PAT up 23.7% YoY to ₹55.56 Cr. For nine months FY26, revenue grew 16.3% to ₹1050.09 Cr and PAT increased 30.7% to ₹154.08 Cr. The company achieved its guided targets for revenue and PAT growth. An earnings call is scheduled for February 03, 2026.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio